Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 26;8(4):102424.
doi: 10.1016/j.rpth.2024.102424. eCollection 2024 May.

Direct oral anticoagulants for treatment of venous thrombosis: illustrated review of appropriate use

Candrika D Khairani  1 , Antoine Bejjani  1 , Ali Assi  1 , Nicole Porio  1 , Azita H Talasaz  2   3 , Gregory Piazza  1   4 , Mary Cushman  5 , Behnood Bikdeli  1   4   6   7
Affiliations

Direct oral anticoagulants for treatment of venous thrombosis: illustrated review of appropriate use

Candrika D Khairani et al. Res Pract Thromb Haemost. .

Abstract

Direct oral anticoagulants (DOACs) have become the preferred option for treatment of venous thromboembolism due to their favorable profile compared with other agents such as vitamin K antagonists or low-molecular-weight heparin. However, findings from randomized controlled trials suggest efficacy and/or safety concerns with DOAC use in some clinical contexts. This illustrated review will summarize indications where DOACs have proven efficacy and safety, situations where they fall short, and situations where uncertainty remains compared with other treatments for venous thromboembolism.

Keywords: Vitamin K Antagonists; anticoagulants; direct oral anticoagulants; low-molecular-weight heparin; venous thromboembolism.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. January C.T., Wann L.S., Calkins H., Chen L.Y., Cigarroa J.E., Cleveland J.C., et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140:e125–e151. - PubMed
    1. De Caterina R., Husted S., Wallentin L., Andreotti F., Arnesen H., Bachmann F., et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis—Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol. 2012;59:1413–1425. - PubMed
    1. Ortel T.L., Neumann I., Ageno W., Beyth R., Clark N.P., Cuker A., et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4:4693–4738. - PMC - PubMed
    1. Stevens S.M., Woller S.C., Baumann Kreuziger L., Bounameaux H., Doerschug K., Geersing G.J., et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160:2247–2259. - PubMed
    1. Agnelli G., Buller H.R., Cohen A., Curto M., Gallus A.S., Johnson M., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799–808. - PubMed

LinkOut - more resources